Anbio Biotechnology Class A Ordinary Shares (NNNN)

DE — Healthcare Sector
Peers: STAA  KMTS  PLSE  BLFS  OPK  NEOG  AZTA  AHCO  IMNM  AMLX 

Automate Your Wheel Strategy on NNNN

With Tiblio's Option Bot, you can configure your own wheel strategy including NNNN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NNNN
  • Rev/Share 0.2093
  • Book/Share 0.4065
  • PB 73.5417
  • Debt/Equity 0.0
  • CurrentRatio 10.712
  • ROIC 0.1253

 

  • MktCap 1312127424.0
  • FreeCF/Share 0.0533
  • PFCF 582.6421
  • PE 493.3474
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 0.1439

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Anbio Biotechnology's Hype And Hard Approvals Suggest A Stretched Valuation
NNNN
Published: October 10, 2025 by: Seeking Alpha
Sentiment: Negative

Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles in both the EU (IVDR transition) and the US (FDA clearance). Likewise, NNNN trades at an extremely high valuation relative to its fundamentals and peers.

Read More
image for news Anbio Biotechnology's Hype And Hard Approvals Suggest A Stretched Valuation
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
NNNN
Published: August 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.

Read More
image for news Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
Anbio Biotechnology Announces Closing of Initial Public Offering
NNNN
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the closing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares (the “Class A Ordinary Shares”) at a public offering price of US$5.00 per Class A Ordinary Share. The Class A Ordinary Shares began trading on the Nasdaq Global Market on February 19, 2025 under the ticker symbol “NNNN.”

Read More
image for news Anbio Biotechnology Announces Closing of Initial Public Offering

About Anbio Biotechnology Class A Ordinary Shares (NNNN)

  • IPO Date 2025-02-19
  • Website https://www.anbio.com
  • Industry Medical - Instruments & Supplies
  • CEO Michael Lau
  • Employees 27
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.